New biomarkers in the risk stratification of patients with suspected acute myocardial infarction.
The acute coronary syndromes (ACS) remain a diagnostic and prognostic challenge for today's physician. Over the past decade, studies have identified several serologic biomarkers to aid the clinician in assessing risk and predicting outcomes in ACS. Still others are being identified that show promise for increasing the accuracy with which this risk is assessed. However, further research remains necessary to identify the perfect cardiac biomarker or combination of markers and to define their roles in clinical management of ACS patients.
Rogers
Bret A
BA
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715-7969, USA.
Newby
L Kristin
LK
D015415:Biomarkers / Q000097:blood*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis* / Q000453:epidemiology; D011379:Prognosis; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D015415:Biomarkers